talactoferrin alfa has been researched along with lactoferrin in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (36.36) | 29.6817 |
| 2010's | 14 (63.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, LD; Dhingra, HM; Falchook, GF; Hayes, BP; Hayes, TG; Smith, DP; Varadhachary, A; Varadhachary, GR | 1 |
| Armstrong, DG; Kirsner, RS; Lavery, L; Lyons, TE; Miller, MS; Reese, A; Serena, T; Sheehan, P; Veves, A; Yankee, EW | 1 |
| McBride, D | 1 |
| Blezinger, P; Cavallo, F; Curcio, C; Engelmayer, J; Forni, G; Pericle, F; Spadaro, M; Varadhachary, A | 1 |
| Caorsi, C; Ceruti, P; Forni, G; Giovarelli, M; Pericle, F; Spadaro, M; Varadhachary, A | 1 |
| Bukowski, RM; Figlin, RA; Hayes, TG; Jonasch, E; Malik, R; Srinivas, S; Stadler, WM; Varadhachary, A | 1 |
| Blezinger, P; Engelmayer, J; Varadhachary, A | 1 |
| Falchook, GS; Hayes, TG; Varadhachary, A | 1 |
| West, HJ | 1 |
| Giaccone, G; Kelly, RJ | 1 |
| Advani, SH; Bapna, A; Digumarti, R; Doval, DC; Julka, PK; Madhavan, J; Malik, R; Nag, S; Parikh, PM; Patil, S; Raman, G; Ranade, AA; Varadhachary, A; Wang, Y | 1 |
| Advani, SH; Bapna, A; Digumarti, R; Ismail, PM; Madhavan, J; Malik, R; Nag, S; Parikh, PM; Patil, S; Sekhon, JS; Vaid, A; Varadhachary, A; Wang, Y; Zhu, J | 1 |
| Reck, M | 1 |
| Bandi, V; Dean, N; Dellinger, RP; Guntupalli, K; Ismail, PM; Levy, M; Lodato, RF; Malik, R; Margolis, B; Morris, PE; Reese, A; Rivers, E; Schaumberg, JP | 1 |
| McCulloh, R; Opal, SM | 1 |
| Bilusic, M; Giaccone, G; Gulley, JL; Jochems, C; Madan, RA; Poole, DJ; Schlom, J; Tsang, KY; Tucker, JA; Vergati, M | 1 |
| Barlesi, F; Chang, A; Crawford, J; Douillard, JY; Giaccone, G; Malik, R; Manegold, C; Owonikoko, T; Perez-Soler, R; Pultar, P; Ramalingam, S; Thatcher, N; Wang, Y; Zhu, J | 1 |
| Chandler, B; Deitch, EA; Feketova, E; Qin, Y; Quackenbush, EJ; Son, JY | 1 |
| Bhattacharya, N; Blenman, KR; Engleman, E; Hwang, G; Lee, PP; Malik, R; Neal, JW; Pultar, P; Riess, JW; San-Pedro Salcedo, M; Wakelee, HA | 1 |
| Du, X; Jiang, R; Lönnerdal, B | 1 |
| Dellinger, RP; Guntupalli, K; Levy, MM; Malik, R; Marshall, JC; Simonson, SG; Singer, M; Vincent, JL | 1 |
| Adamkin, DH; Niklas, V; Petrak, K; Radmacher, P; Sherman, J; Sherman, MP; Wertheimer, F | 1 |
3 review(s) available for talactoferrin alfa and lactoferrin
| Article | Year |
|---|---|
Novel targeted agents for lung cancer.
Topics: Antigens, Neoplasm; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Heat-Shock Proteins; Humans; Immunotherapy; Lactoferrin; Lung Neoplasms; Membrane Glycoproteins; Mucin-1; Neoplasm Proteins; Receptor, IGF Type 1; Recombinant Proteins | 2009 |
The role of talactoferrin alpha in the treatment of non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Evaluation, Preclinical; Evidence-Based Medicine; Humans; Lactoferrin; Lung Neoplasms; Treatment Outcome | 2010 |
What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?
Topics: Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carboplatin; Carcinoma, Non-Small-Cell Lung; CTLA-4 Antigen; Disease-Free Survival; Humans; Immunotherapy; Ipilimumab; Lactoferrin; Lung Neoplasms; Membrane Glycoproteins; Neoplasm Proteins; Nivolumab; Paclitaxel | 2012 |
10 trial(s) available for talactoferrin alfa and lactoferrin
| Article | Year |
|---|---|
Phase I trial of oral talactoferrin alfa in refractory solid tumors.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Humans; Interleukin-18; Lactoferrin; Male; Middle Aged; Neoplasms; Recombinant Proteins | 2006 |
Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study.
Topics: Administration, Topical; Diabetic Foot; Dose-Response Relationship, Drug; Female; Humans; Lactoferrin; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Single-Blind Method; Treatment Outcome; Wound Healing | 2007 |
Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Lactoferrin; Male; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Survival Analysis | 2008 |
Phase IB trial of oral talactoferrin in the treatment of patients with metastatic solid tumors.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cell Proliferation; Demography; Female; Humans; Kidney Neoplasms; Lactoferrin; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Tomography, X-Ray Computed | 2010 |
A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Female; Humans; Lactoferrin; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Analysis; Treatment Outcome | 2011 |
Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lactoferrin; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Platinum Compounds; Proportional Hazards Models; Treatment Failure; Treatment Outcome | 2011 |
A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis.
Topics: Adult; Aged; APACHE; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hospital Mortality; Humans; Infusions, Parenteral; Intensive Care Units; Lactoferrin; Male; Middle Aged; Placebos; Prospective Studies; Recombinant Proteins; Sepsis; Treatment Outcome | 2013 |
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Immunotherapy; Kaplan-Meier Estimate; Lactoferrin; Male; Middle Aged; Neoplasm Staging; Placebos; Treatment Outcome | 2013 |
Talactoferrin in Severe Sepsis: Results From the Phase II/III Oral tAlactoferrin in Severe sepsIS Trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; APACHE; Double-Blind Method; Female; Humans; Lactoferrin; Male; Middle Aged; Sepsis; Shock, Septic | 2015 |
Randomized Controlled Trial of Talactoferrin Oral Solution in Preterm Infants.
Topics: Administration, Oral; Bacteremia; Cross Infection; Double-Blind Method; Enterocolitis, Necrotizing; Female; Follow-Up Studies; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Lactoferrin; Male; Meningitis; Pneumonia; Protective Agents; Sepsis; Treatment Outcome; Urinary Tract Infections | 2016 |
9 other study(ies) available for talactoferrin alfa and lactoferrin
| Article | Year |
|---|---|
Talactoferrin alpha receives fast-track designation for the treatment of non-small cell lung cancer.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Drug Approval; Humans; Lactoferrin; Lung Neoplasms; Placebos; Randomized Controlled Trials as Topic; Recombinant Proteins; Survival Rate; United States; United States Food and Drug Administration | 2007 |
Requirement for IFN-gamma, CD8+ T lymphocytes, and NKT cells in talactoferrin-induced inhibition of neu+ tumors.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Female; Interferon-gamma; Killer Cells, Natural; Lactoferrin; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; Peyer's Patches; Receptor, ErbB-2 | 2007 |
Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells.
Topics: Cell Differentiation; Cytokines; Dendritic Cells; Humans; Immunity, Innate; In Vitro Techniques; Lactoferrin; Lymphocyte Activation; Models, Biological; Monocytes; Recombinant Proteins; T-Lymphocytes | 2008 |
Talactoferrin stimulates wound healing with modulation of inflammation.
Topics: Administration, Cutaneous; Animals; Diabetes Complications; Humans; Inflammation Mediators; Jurkat Cells; Lactoferrin; Male; Mice; Mice, Inbred ICR; Soft Tissue Injuries; Wound Healing | 2008 |
Human recombinant lactoferrin for sepsis: too good to be true?.
Topics: Female; Humans; Lactoferrin; Male; Sepsis | 2013 |
Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; CD4-Positive T-Lymphocytes; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Immune System; Interleukin-6; Killer Cells, Natural; Lactoferrin; Lung Neoplasms; Male; Neoplasm Staging; Pilot Projects; T-Lymphocytes, Regulatory; Tumor Necrosis Factor-alpha | 2013 |
Oral pretreatment with recombinant human lactoferrin limits trauma-hemorrhagic shock-induced gut injury and the biological activity of mesenteric lymph.
Topics: Administration, Oral; Animals; Ileum; Lactoferrin; Laparotomy; Lymph; Lymphatic System; Male; Neutrophils; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Reperfusion Injury; Respiratory Burst; Shock, Hemorrhagic; Wounds and Injuries | 2014 |
Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lactoferrin; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local | 2014 |
Comparison of bioactivities of talactoferrin and lactoferrins from human and bovine milk.
Topics: Animals; Apoptosis; Caco-2 Cells; Cattle; Cell Proliferation; Chemokine CCL20; Colonic Neoplasms; Enterocolitis, Necrotizing; Escherichia coli; HT29 Cells; Humans; Intestinal Mucosa; Intestines; Lactoferrin; Liver; Milk; Milk, Human; Transforming Growth Factor beta1 | 2014 |